PIK3CA and breast carcinoma: Given the substantial overlap of PIK3CA status in primary tumors and metastases, the choice of what sample to test in HR+/HER2− breast cancer should be primarily driven by the quality and quantity of FFPE material available, regardless of the anatomical site.